Fig. 3From: Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trialsEstimated yearly risk of MACE as a function of CV risk. Absolute yearly MACE probabilities for semaglutide and comparators, respectively, estimated using a non-stratified Cox proportional hazards model including effects of treatment, CV risk score and interaction between both. The x-axis shows the CV risk score derived from subjects’ baseline characteristics in the semaglutide trials. Data on graph cut off at the 5th and 95th percentile of the whole dataset. CV cardiovascular, MACE major adverse cardiovascular events, NNT number needed to treat to avoid one MACE during 1 yearBack to article page